Profiel
Dr. Anshul Dhankher is an Analyst at LifeSci Capital LLC.
Dr. Dhanker spent two years in the Operations Development Program at AbbVie, rotating through multiple research departments to learn about drug development in the pharmaceutical industry.
He received an undergraduate degree from Carnegie Mellon University and a doctorate from Georgia Institute of Technology.
He holds the Series 7, 86, and 87
Actieve functies van Anshul Dhankher
Bedrijven | Functie | Begin |
---|---|---|
LifeSci Capital LLC
LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Analyst-Equity | 01-09-2021 |
Opleiding van Anshul Dhankher
Carnegie Mellon University | Undergraduate Degree |
Georgia Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
LifeSci Capital LLC
LifeSci Capital LLC Investment Banks/BrokersFinance LifeSci Capital LLC is a full-service investment bank that offers financial and strategic advisory services, institutional outreach, and research to leading life sciences companies. The private company is based in New York, NY. The company's team of investment bankers has extensive experience at bulge bracket and specialty investment banks. LifeSci Capital's highly regarded team of analysts generates differentiated, proprietary research and covers companies across all major therapeutic areas. The company was founded in 2013 by Andrew Ian McDonald and Michael Yehuda Rice. Andrew Ian McDonald has been the CEO since 2013. | Finance |